Results 311 to 320 of about 1,166,644 (417)

Effects of Cholestatic Hepatic Disease and Chronic Renal Failure on Alfentanil Pharmacokinetics in Children

open access: bronze, 1989
Peter J. Davis   +5 more
openalex   +1 more source

Prophylactic IABP Use in Protected PCI Reduces Infarction Size and Leads to More Complete Revascularization in Comparison to Rescue IAPB Use

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background There is little data questioning the timing of intra‐aortic balloon pump (IABP) implantation in non‐cardiogenic shock patients undergoing high‐risk percutaneous procedures. Aims We compared prophylactic IABP (P‐IABP) implantation to an emergent, unplanned rescue use (R‐IABP) in high‐risk PCI. Methods Among 300 IAPB patients who were
Sascha d'Almeida   +8 more
wiley   +1 more source

Outcomes Beyond 10 Years After Transcatheter Aortic Valve Implantation in High‐Risk Patients With Severe Aortic Valve Stenosis

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Limited data is available on long‐term outcomes and valve durability measures of transcatheter aortic valve implantation (TAVI). Aims This study sought to assess clinical and echocardiographic outcomes of high‐risk patients during the early experience of TAVI with a follow‐up period extending beyond 10 years.
Ellen Dietze   +14 more
wiley   +1 more source

Epigenetic Changes Related to Hypertension in Asian Adults: A Systematic Review

open access: yesChronic Diseases and Translational Medicine, EarlyView.
PRISMA study flow diagram. ABSTRACT Background Elevated high blood pressure is controlled by complicated, little‐understood genetic and epigenetic pathways that are influenced by both heritable and environmental variables. Many adult systolic and diastolic blood pressure‐related genomic loci have been identified through previous genome‐wide association
Lilik Sukesi   +7 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez   +5 more
wiley   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han   +16 more
wiley   +1 more source

Soluble interleukin-2 receptors in the serum of patients with chronic renal failure.

open access: bronze, 1988
Teruyuki Takamatsu   +5 more
openalex   +2 more sources

A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE Activity

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Accurately assessing glomerular filtration rate (GFR) from plasma creatinine concentrations is challenging in patients with unstable renal function. This study aimed to refine the understanding of creatinine kinetics for more reliable assessments of GFR and net creatinine tubular secretion (nCTS) via OCT2/MATE in humans.
Zhendong Chen   +5 more
wiley   +1 more source

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy